Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Stella acts as an intermediary. Researcher contact info is never exposed.